

Revisiting Short-Chain Fatty Acids and the Microbiota in Colorectal Cancer

Running title: SCFAs and Colorectal Cancer

Marc A Sze¹, Nicholas A Lesniak¹, Mack T Ruffin IV², Patrick D. Schloss^{1†}

† To whom correspondence should be addressed: pschloss@umich.edu

¹ Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109

² Department of Family Medicine and Community Medicine, Penn State Hershey Medical Center, Hershey, PA

1 Abstract

2 Introduction

3 Results

4 Discussion

5 Conclusions

6 **Materials and Methods**

7 **Study design and sampling.** The overall protocol has been described in detail previously (1, 2).
8 In brief, this study used fecal samples obtained at either a single cross-sectional time point (n=490)
9 or from before and after treatment for their tumor (n=67). For patients undergoing treatment for their
10 tumor the length of time between their initial and follow up sample ranged from 188 - 546 days. Our
11 use of treatment has been previously defined as encompassing removal of a tumor with or without
12 chemotherapy and radiation (1). Diagnosis of tumor was made by colonoscopic examination and
13 histopathological review of biopsies obtained (1, 2). The University of Michigan Institutional Review
14 Board approved the study and informed consent was obtained from all participants in accordance
15 to the guidelines set out by the Helsinki Declaration.

16 **Measuring specific SCFAs.** Our protocol for the measurement of acetate, butyrate, and propionate
17 followed a previously published protocol (3). The following changes to this protocol included the
18 use of frozen fecal samples suspended in 1ml of PBS instead of fecal suspensions in DNA Genotek
19 OmniGut tubes, and the use of the actual weight of fecal samples instead of the average weight for
20 SCFA concentration normalizations. These changes did not affect the overall median concentrations
21 of these SCFAs between the two studies (see Table 1 (3) and Figure 1 in this report).

22 **16s rRNA gene sequencing.** The workflow and processing have been described previously (1,
23 4, 5). The major differences from these previous reports include: the use of version 1.39.5 of the
24 mothur software package and clustering Operational Taxonomic Units (OTUs) at 97% similarity
25 used the OptClust algorithm (6).

26 **Generating imputed metagenomes.** The use of PICRUSt version 1.1.2 with the recommended
27 standard operating protocol (7) was used. Briefly, the mothur shared file and metadata was
28 converted into a biom formatted table using the biom convert function, the subsequent biom
29 file was processed with the normalize_by_copy_number.py function, and subsequent imputed
30 metagenomes created using the predict_metagenomes.py function.

31 **Obtaining OPFs from metagenomes.** A subset of the cross-sectional group (n=490) containing
32 a total of 85 individuals (normal n=29 normal, adenoma n=28, and carcinoma n=28) was shotgun

33 sequenced on an Illumina HiSeq with 125 bp paired end reads using a previously described method
34 (8). Briefly, the sequences were quality filtered and sequences aligning to the human genome
35 were removed prior to contig assembly with MEGAHIT (9). Open Reading Frames (ORFs) were
36 identified using Prodigal (10), counts generated using Diamond (11), subsequent clustering into
37 Operational Protein Families (OPFs) used mmseq2 (12), and OPF gene alignment used the KEGG
38 database (13).

39 **Statistical analysis workflow.**

40 **Acknowledgements**

41 The authors thank the Great Lakes-New England Early Detection Research Network for providing
42 the fecal samples that were used in this study. We would also like to thank Kwi Kim and Thomas M
43 Schmidt for their help in running the short-chain fatty acid analysis on the High-Performance Liquid
44 Chromatography machine at the University of Michigan. Salary support for Marc A. Sze came from
45 the Canadian Institute of Health Research and NIH grant UL1TR002240. Salary support for Patrick
46 D. Schloss came from NIH grants P30DK034933 and 1R01CA215574.

References

1. **Sze MA, Baxter NT, Ruffin MT, Rogers MAM, Schloss PD.** 2017. Normalization of the microbiota in patients after treatment for colonic lesions. *Microbiome* **5**. doi:10.1186/s40168-017-0366-3.
2. **Baxter NT, Ruffin MT, Rogers MAM, Schloss PD.** 2016. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. *Genome Medicine* **8**. doi:10.1186/s13073-016-0290-3.
3. **Venkataraman A, Sieber JR, Schmidt AW, Waldron C, Theis KR, Schmidt TM.** 2016. Variable responses of human microbiomes to dietary supplementation with resistant starch. *Microbiome* **4**. doi:10.1186/s40168-016-0178-x.
4. **Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA, Oakley BB, Parks DH, Robinson CJ, Sahl JW, Stres B, Thallinger GG, Horn DJV, Weber CF.** 2009. Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. *Applied and Environmental Microbiology* **75**:7537–7541. doi:10.1128/aem.01541-09.
5. **Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD.** 2013. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq illumina sequencing platform. *Applied and Environmental Microbiology* **79**:5112–5120. doi:10.1128/aem.01043-13.
6. **Westcott SL, Schloss PD.** 2017. OptiClust, an improved method for assigning amplicon-based sequence data to operational taxonomic units. *mSphere* **2**:e00073–17. doi:10.1128/mspheredirect.00073-17.
7. **Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC, Burkepile DE, Thurber RLV, Knight R, Beiko RG, Huttenhower C.** 2013. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. *Nature Biotechnology*

- 71 **31:814–821. doi:10.1038/nbt.2676.**
- 72 **8. Hannigan GD, Duhaime MB, Ruffin MT, Koumpouras CC, Schloss PD.** 2017. Diagnostic
73 potential & the interactive dynamics of the colorectal cancer virome. doi:10.1101/152868.
- 74 **9. Li D, Liu C-M, Luo R, Sadakane K, Lam T-W.** 2015. MEGAHIT: An ultra-fast single-node
75 solution for large and complex metagenomics assembly via succinct de bruijn graph. Bioinformatics
76 **31:1674–1676. doi:10.1093/bioinformatics/btv033.**
- 77 **10. Hyatt D, Chen G-L, LoCascio PF, Land ML, Larimer FW, Hauser LJ.** 2010. Prodigal:
78 Prokaryotic gene recognition and translation initiation site identification. BMC Bioinformatics **11:119.**
79 doi:10.1186/1471-2105-11-119.
- 80 **11. Buchfink B, Xie C, Huson DH.** 2014. Fast and sensitive protein alignment using DIAMOND.
81 Nature Methods **12:59–60. doi:10.1038/nmeth.3176.**
- 82 **12. Steinegger M, Söding J.** 2017. MMseqs2 enables sensitive protein sequence searching for
83 the analysis of massive data sets. Nature Biotechnology. doi:10.1038/nbt.3988.
- 84 **13. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M.** 2015. KEGG as a
85 reference resource for gene and protein annotation. Nucleic Acids Research **44:D457–D462.**
86 doi:10.1093/nar/gkv1070.

87 Insert figure legends with the first sentence in bold, for example:

88 **Figure 1. Number of OTUs sampled among bacterial and archaeal 16S rRNA gene**
89 **sequences for different OTU definitions and level of sequencing effort.** Rarefaction curves
90 for different OTU definitions of Bacteria (A) and Archaea (B). Rarefaction curves for the coarse
91 environments in Table 1 for Bacteria (C) and Archaea (D).